250 Million EUR Research Programme on Neurodegeneration Featured at Alzheimer Europe Conference

THE HAGUE, Netherlands - Sept. 26, 2019 - PRLog -- In recent years, European research projects have brought many crucial stakeholders together. Four Neuronet sessions, as part of the Alzheimer Europe Conference, will provide insights from research projects that have been launched by the Innovative Medicines Initiative (IMI), Europe's biggest public-private partnership in the life sciences.

The Neuronet sessions will introduce the IMI and its neurodegeneration portfolio. The programme is listed below:

Thursday, 24 October, 10.30-12.00

Parallel session P5. European research collaboration in Alzheimer's disease and beyond

The Innovative Medicines Initiative and its neurodegeneration portfolio

Neuronet – Efficiently Networking European Neurodegeneration Research

Patient and Public Involvement in the IMI research portfolio

Thursday, 24 October, 14.00-15.30

Parallel session P13. From risk to dementia – Understanding disease progression and its causes

ADAPTED – Alzheimer's disease apolipoprotein pathology for treatment elucidation and development

PHAGO – Targeting TREM2 and CD33 of phagocytes for treatment of Alzheimer's disease

AETIONOMY – Disease Mechanisms for Patient Subgroup Identification and Disease Progression Modeling

Friday, 25 October, 10.30-12.00

Parallel session P21. Improving data access and the development of predictive models

EQIPD – Data quality in preclinical research

EMIF – European Medical Information Framework

ROADMAP – Real world outcomes across the AD spectrum

IM2PACT – Discovery of blood-brain barrier targets and transport pathways to treat neuro/metabolic diseases – A public-private partnership

Friday, 25 October, 14.00-15.30

Parallel session P29. Diagnosis, patient engagement and trials

AMYPAD – Amyloid imaging to prevent Alzheimer's disease

EPAD – European prevention of Alzheimer's dementia consortium

MOPEAD – Models of Patient Engagement in Alzheimer's Disease: a European project to develop and test innovative patient engagement strategies

RADAR-AD – Remote Assessment of functional decline in Alzheimer's Disease

For more information visit: https://www.imi-neuronet.org/2019-event-the-hague/